Navigation Links
NuVasive to Host Investor Reception on September 11, 2007
Date:9/7/2007

Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.

The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.

NuVasive senior management at the reception will include:

* Alex Lukianov, Chairman and Chief Executive Officer

* Keith Valentine, President and Chief Operating Officer

* Kevin O'Boyle, Executive Vice President and Chief Financial Officer

* Pat Miles, Executive Vice President of Marketing and Development

* Jeff Rydin, Senior Vice President, U.S. Sales

* Jason Hannon, Senior Vice President and General Counsel

Participants in the physician panel will include:

* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant

Clinical Professor at SUNY, Buffalo, NY

* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine

Institute, Austin, TX

* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and

Beth Israel Hospitals and Assistant Professor of Neurological
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Investor warns of angel-venture funding gap
3. Brazilian bio-industry should impress American investors
4. Investors raise $25 million for biodiesel plant
5. Bio-energy and cleantech grab attention of investors
6. Venture Investors to open Michigan office
7. Early-stage executives hear from investors
8. Commerce qualifies seven for investor tax credits
9. Investor links East Coast funds to Midwest tech
10. Angel investors commit $12.7B in first half of `06
11. Wisconsin investors the lifeblood of New Jersey biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues  ("BioLife" or the "Company"), today announced that it ... 4, 2015 (the "Annual Meeting"). Because the expected ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tetrachloroethylene (PCE) -- found to have contaminated drinking water ... to 1985 have been linked to certain diseases and ... the National Research Council, Contaminated Water Supplies at Camp ... about the potential adverse health effects that could occur ...
... b3c newswire / - Dutch biotechnology company ... Scientific Research TNO today announced that they have entered ... viral gene delivery platform SVac . Under this agreement, ... and testing of viral gene delivery systems such as ...
... Society for Microbiology (ASM) Siemens Healthcare Diagnostics ... Melissa B. Miller, Ph.D., D(ABMM), director, Clinical ... Pathology and Laboratory Medicine, and associate director, ... North Carolina (UNC) School of Medicine, Chapel ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
Biology Products: